Atlas Trials

Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

Clinical trial NCT02576977 · TERMINATED

Trial details

NCT number
NCT02576977
Sponsor
Merck Sharp & Dohme LLC
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2015-10-19
Primary completion
2018-07-09
Enrollment
251

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.